Boulder Care Reaches Agreement with Cone Health to Expand Access to Telehealth Addiction Treatment in North Carolina
'It's a privilege to partner with Cone Health to extend high-quality healthcare to our communities: ensuring care continuity, quality, and flexibility for patients to access care anywhere they are.' — Stephanie Strong, CEO and Founder of Boulder Care
GREENSBORO, NC, UNITED STATES, May 6, 2025 / EINPresswire.com / -- Boulder Care, a leading provider of telehealth-based addiction treatment, is proud to announce a new agreement with Cone Health to expand access to critical care for individuals living with opioid and alcohol use disorders in North Carolina. The collaboration will bring Boulder's telehealth model of care—grounded in respect, compassion, and long-term support—to individuals in Greensboro and beyond, ensuring that people living with substance use disorders have access to the care they need, when they need it.
Stephanie Strong, founder and CEO of Boulder Care and native North Carolinian, commented on the news, 'Boulder's low-barrier care model helps patients access immediate help for their addiction, and remain in treatment long-term without taking time away from their work or families. It's a privilege to partner with Cone Health to extend high-quality healthcare to our communities: ensuring care continuity, quality, and flexibility for patients to access care anywhere they are.'
The new agreement will allow Cone Health's Behavioral Health Services to refer individuals to Boulder Care, which offers a comprehensive suite of services, including medication-assisted treatment (MAT) and evidence-based recovery support services. With Boulder's telehealth capabilities, patients can access these services from the comfort and privacy of their own homes, using smartphones, tablets, or computers.
'When a person struggling with addiction makes the decision to get help, we want to provide that help as soon as possible,' says Dave Jenkins, the executive director of Cone Health Behavioral Health Services, 'Having treatment available through telehealth makes it even easier to provide the care and support we want to provide our patients.'
The collaboration will focus on individuals aged 18 and older living with opioid use disorder (OUD) or alcohol use disorder (AUD) who are seeking telehealth addiction treatment. Patients will receive customized care plans tailored to their specific recovery goals, with a focus on long-term wellness and harm reduction.
Boulder's commitment to evidence-based, longitudinal treatment aims to reduce the risk of overdose and other adverse health outcomes associated with substance use. The collaboration also emphasizes the importance of addressing social determinants of health and working closely with community organizations to ensure a holistic approach to addiction recovery.
If you or someone you know is interested in learning more about Boulder's treatment options, please download the Boulder Care app on your mobile phone or visit https://www.boulder.care/get-started to enroll. You can also enroll by telephone at 866-901-4860. Boulder accepts Medicaid, Medicare, and most insurance plans.
About Boulder Care
Boulder is a leader in high-quality addiction medicine, providing evidence-based treatment for opioid and alcohol use over telehealth. Dedicated care teams collaborate to provide low-barrier access to medication-based treatment and emphasize long-term support as patients work toward unique recovery goals. Boulder partners with health plans and community organizations to offer affordable treatment to patients across the U.S. Learn more about Boulder's mission to improve the lives of people with substance use disorders at www.boulder.care or contact us at [email protected].
Katie ONeill
Boulder Care
email us here
Visit us on social media:
X
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
an hour ago
- Fox News
Needle-free vaccine method delivers antibodies through dental floss in early study
Dental floss could eventually do much more than improve oral hygiene. A new study led by Texas Tech University and the University of North Carolina suggests that the thin filament could eventually double as a vaccine mechanism. In animal models, the researchers showed that dental floss can effectively release vaccines through the tissue between the teeth and gums, according to a press release. In the study, the flossing technique triggered the production of antibodies in "mucosal surfaces," such as the lining of the nose and lungs, the release stated. The findings were published in the journal Nature Biomedical Engineering. "Mucosal surfaces are important, because they are a source of entry for pathogens, such as influenza and COVID," said co-author Harvinder Singh Gill, professor of chemical and biomolecular engineering at North Carolina State University, in the release. With the traditional method of injecting vaccines, the antibodies are primarily produced in the bloodstream, he noted. "But we know that when a vaccine is given via the mucosal surface, antibodies are stimulated not only in the bloodstream, but also on mucosal surfaces," said Gill. "This improves the body's ability to prevent infection, because there is an additional line of antibody defense before a pathogen enters the body." The vaccine enters through the "junctional epithelium," which is a thin layer of tissue in the deep pocket between the tooth and the gum. This tissue doesn't have the same barrier as other tissue linings, which means it can release immune cells into the body. In the study, the researchers added a peptide flu vaccine to unwaxed dental floss before flossing the teeth of lab mice, according to the release. Next, they compared the effectiveness of the floss-delivered vaccine to techniques that delivered it nasally or orally. "It would be easy to administer, and it addresses concerns many people have about being vaccinated with needles." "We found that applying vaccine via the junctional epithelium produces a far superior antibody response on mucosal surfaces than the current gold standard for vaccinating via the oral cavity, which involves placing vaccine under the tongue," said first author Rohan Ingrole, a Ph.D. student at Texas Tech University. "The flossing technique also provides comparable protection against the flu virus as compared to the vaccine being given via the nasal epithelium." In addition to flu, the test was repeated for three other vaccine types: proteins, inactivated viruses and mRNA. For all types, the flossing technique produced "robust antibody responses in the bloodstream and across mucosal surfaces," the release stated. Next, the research team aims to test the effectiveness of vaccine delivery to the epithelial junction in humans through the use of floss picks, which are easier to hold. "It would be easy to administer, and it addresses concerns many people have about being vaccinated with needles," Gill said. "And we think this technique should be comparable in price to other vaccine delivery techniques." Hua Wang, assistant professor of materials science and engineering at the University of Illinois' Grainger College of Engineering, was not involved in the study but shared his reaction to the findings. "This study presents a promising floss-based vaccination method that can avoid needle injection or any potentially painful procedure," he told Fox News Digital. "The authors demonstrated that vaccine components in the floss coating can penetrate the junctional epithelium in gingival sulcus and reach the underlying tissues, leading to systemic antibody responses." The floss-based vaccination method could help to improve patient compliance if it goes through the full evaluation process, he noted. There are some limitations and drawbacks associated with floss-based vaccines, the researchers acknowledged. Babies and toddlers who don't have teeth yet wouldn't be candidates for the technique, for example. "In addition, we would need to know more about how or whether this approach would work for people who have gum disease or other oral infections," Gill added. Wang agreed that many questions remain to be answered about this experimental vaccination method. "In addition to the unclear impact of gingival tissue infection on vaccination, the local and systemic side effects of this vaccination method remain to be understood," he told Fox News Digital. "For example, vaccination at the gingival tissue may initiate local inflammation that eventually induces undesirable side effects." It's also not yet clear what exact path the vaccine components follow when traveling from the tooth site to the tissues or how the immune responses are generated, Wang noted. For more Health articles, visit "Lastly, from the translation perspective, the efficacy of floss-based vaccines would need to be comparable to conventional needle-based vaccines." The study was funded by the National Institutes of Health (NIH) and by funds from the Whitacre Endowed Chair in Science and Engineering at Texas Tech University.
Yahoo
5 hours ago
- Yahoo
6 Marinara Sauce Recalls That Swept Across The US
Thanks in part to its inclusion in an array of popular dishes, marinara sauce recalls throughout the years have impacted wide swaths of the American public. Derived from the Italian "alla marinara," which translates to "in sailor style," the simple sauce combining tomatoes with garlic, onions, and spices is a feature of pizza parties and spaghetti nights alike. However, meal plans have been sidetracked a number of times in the past over marinara recalls involving risks of allergens, molds, and even labeling issues. Triggering swelling, a rash, or a more serious medical crisis is a surefire way to spoil someone's meatball sub or their chicken parmesan. Fortunately for consumers -- and the retailers and restaurants bringing the sauce to tables across the nation — safety measures and oversight have kept occurrences to a minimum. Still, when issues have arisen similar to the cases that follow, the scope has sometimes encompassed tens of thousands of pounds worth of marinara. Read more: Secret Ingredients You Should Be Using In Your Spaghetti Sauce Scratch Pasta Co. Marinara Sauce Recall (2023) As far as the North Carolina Department of Agriculture (NCDA) is concerned, precision is paramount when it comes to declaring allergens. So it was that when an inspection at the Henderson, North Carolina facility of Carolina CoPacking, LLC reviewed jars of Scratch Pasta Co.'s marinara sauce, a lack of clarity on milk -- one of the nine major food allergens -- was enough to trigger a recall. Along with the peeled San Marzano plum tomatoes and onion, the description on the 24.5-ounce glass jars listed butter -- one of a number of ways to upgrade pasta sauce -- as an ingredient. Whether or not it may be considered common knowledge that butter is a dairy product derived from churning cream was of no consequence for inspectors tasked with ensuring public health. The law requires the allergen be specifically identified if the ingredient does not already contain the common name of the source. As such, over 1,800 jars that had been shipped to Virginia were recalled in December 2023. Hungryroot Marinara Sauce Recall (2023) Those seeking the convenience of a subscription service hit a snag in July 2023 when a key ingredient in many pasta dishes was reported to contain yeast and mold. After its initial launch by founder Ben McKean in 2015, Hungryroot had expanded in 2019 from delivering its own line of ingredients for meals in minutes to become a grocery service. Among the products offered, Hungryroot's marinara sauce, manufactured by the Gloucester, Massachusetts-based BC Gourmet USA, Inc., was found to have a fungus issue in 2023. Deemed to be a Class II recall by the U.S. Food & Drug Administration (FDA), meaning a potential for temporary and reversible health consequences was present, over 81,300 10.5-ounce cups of the marinara sauce were impacted by the recall. Additionally, nearly 13,000 10.5-ounce cups of vodka sauce posed the same risk as the product was recalled from California, Indiana, and New Jersey. Considering the amount of time unopened marinara remains shelf stable -- up to 18 months -- versus how long it stays fresh in the fridge, it wasn't until the following July that the matter was officially considered closed. Mid's Mideo's Marinara Sauce Recall (2021) Macronutrients may get the most attention when consumers inspect their purchases, attempting to find the ideal balance of carbohydrates, fats, and proteins to balance their diet, but the other details often proven more critical for those with dietary restrictions. For example, those who already experience hyperkalemia, a condition with high levels of the electrolyte potassium in their blood, may well have been at risk of severe health consequences over an error involving Mid's Mideo's Marinara in 2021. Designated as a Class II risk by the FDA, almost 160,000 32-ounce jars of the sauce produced by RC Industries Inc. was recalled in May of that year after it was determined that the incorrect amount of potassium per serving was listed on the label. While electrolytes like potassium are known for their important role in aiding hydration, those experiencing hyperkalemia can experience irregular heartbeats, digestive issues, and numbness or weakness in their muscles, typically brought on by kidney disease as the organs struggle to remove the excess potassium from the body. Victoria Marinara Sauce Recall (2019) Thanks to inspection processes and safety procedures, many mishaps that could prove harmful to consumers are caught before products ever leave their manufacturing facilities. That wasn't the case in February 2019 when a customer reported an alleged allergic reaction to B&G Foods related to the presence of cashews. As a result, a recall was issued for almost 1,300 cases of 40-ounce jars of Victoria Marinara Sauce. As with fish allergens, companies are required by law to indicate the specific type of tree nut that is either included in the food or that may have come in contact with it during production. The latter is considered the most common cause for contamination with undeclared allergens according to the organization Kids with Food Allergies. Though not actually a nut by botanical standards -- instead landing beside coffee beans, olives, and peaches under the drupe designation -- cashews are considered a tree nut where allergies are concerned. Included with the recall, B&G Foods Executive Vice President of Operations William Herbes had assured that the company observes "the highest ethical standards" and that its founding values would guide them in addressing the issue. Lidia's Marinara Sauce Recall (2017) A simple mistake wasn't so simple for Woodbury, New York's Nonna Foods in March 2017 when a mixup impacted marinara shipped to 40 states, as well as to the nation's capital. It was then that the erroneous packaging of Lidia's Vodka Sauce with labels for Lidia's Marinara Sauce resulted in scores of jars posing a potential life-threatening risk. Specifically, since the marinara sauce does not contain milk, and the vodka sauce does (even though it doesn't need vodka), consumers sensitive to the allergen wouldn't be aware of the potential exposure. Were someone with a milk allergy to unwittingly eat the sauce, an immune response to one of the two primary proteins in the milk would result in symptoms like digestive issues, chest tightness, or a lose of consciousness. The vast amount of protein in milk is casein at around 80% while whey comprises roughly 20%. Fortunately for Nonna's there were no reports of illness tied the distribution of about 750 jars with the incorrect label. Mazzio's Marinara Sauce Recall (2012) Another milk mishap occurred in 2012 after the Oklahoma-based pizza chain Mazzio's received an ill-fated supply of marinara. A key difference between pizza sauce and marinara involves the application of heat to the latter unlike the simply stirred together ingredients of the former. The business that began as school teacher Ken Selby's The Pizza Parlor in 1961 had been sent over 6,300 cases of marinara from supplier Paradise Tomato Kitchens Inc. that neglected to detail the presence of milk. Specifically, the packaging didn't explain that the butter used in preparing the sauce was a product that came from milk. The issue was considered a Class II recall by the FDA and the cases -- that each contained six 6.65 pound pouches -- amounted to more than 253,000 pounds of marinara getting pulled from the market in order to prevent any adverse reactions. The year 2012 was also when that Paradise Tomato Kitchens had celebrated its growth to manufacturing over 120 products a year after expanding production with the opening of a third plant in Los Banos, California on top of the two located in Kentucky. Want more food knowledge? Sign up to our free newsletter where we're helping thousands of foodies, like you, become culinary masters, one email at a time. Read the original article on Food Republic. Solve the daily Crossword
Yahoo
6 hours ago
- Yahoo
What To Expect From Hims & Hers Health's (HIMS) Q2 Earnings
Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting results this Monday after market hours. Here's what to expect. Hims & Hers Health beat analysts' revenue expectations by 8.3% last quarter, reporting revenues of $586 million, up 111% year on year. It was a strong quarter for the company, with a solid beat of analysts' EPS estimates and full-year EBITDA guidance beating analysts' expectations. It added 137,000 customers to reach a total of 2.37 million. Is Hims & Hers Health a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Hims & Hers Health's revenue to grow 74.5% year on year to $550.8 million, improving from the 51.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.23 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hims & Hers Health has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 3.2% on average. Looking at Hims & Hers Health's peers in the healthcare technology segment, only Omnicell has reported results so far. It beat analysts' revenue estimates by 4.9%, delivering year-on-year sales growth of 5%. The stock price was unchanged following the results. Read our full analysis of Omnicell's earnings results here. Debates around the economy's health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare technology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Hims & Hers Health is up 29% during the same time and is heading into earnings with an average analyst price target of $48.36 (compared to the current share price of $62.48). Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
